Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Systemic Lupus Erythematosus

NCT06518668 is registered in ClinicalTrials.gov with Hospital for Special Surgery, New York as lead sponsor.

NCT NCT06518668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06518668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Lead sponsor
Hospital for Special Surgery, New York
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
July 1, 2024
Completion date
December 31, 2040
Enrollment
6 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus